Total RNA-seq of C2C12 myotubes treated with agrin or MuSK antibodies
Total RNA-seq was performed to investigate if MuSK antibody binding directly affects (NMJ) gene expression in muscle cells. C2C12 differentiated myotubes were treated for 16 hours with bivalent MuSK antibodies (activating MuSK signaling) or functionally monovalent MuSK antibodies (inhibiting agrin-induced MuSK signaling) derived from B-cell receptor sequences from a MuSK myasthenia gravis patient. The total RNA transcriptome was compared to treatment with agrin (the natural activator of MuSK) or a negative control antibody targeting a protein not present in myotubes. Overall design: RNA-seq profiling of C2C12 differentiated myotubes treated with bivalent MuSK antibodies (13-3B5) or agrin + monovalent MuSK antibodies (13-3B5xb12 or 11-3F6xb12). For each condition 4 biological replicates were generated and used for statistical analysis.